[G22-40] Axicabtagene ciloleucel (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

Last updated 12.01.2023

Project no.:
G22-40

Commission:
Commission awarded on 15.11.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Withdrawn commission

Department/Division:
Health Economics

Topic:
Cancer

Note:

In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form